Zydus surges on receiving final approval from the USFDA for Voriconazole Tablets

27 May 2016 Evaluate

Cadila Healthcare is currently trading at Rs. 329.25, up by 8.90 points or 2.78% from its previous closing of Rs. 320.35 on the BSE.

The scrip opened at Rs. 321.00 and has touched a high and low of Rs. 330.80 and Rs. 321.00 respectively. So far 62732 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 295.50 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 330.80 and Rs. 316.20 respectively. The current market cap of the company is Rs. 33691.37 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 13.85% and 11.36% respectively.

Zydus Cadila has received the final approval from the USFDA to market Voriconazole Tablets in strengths of 50 mg and 200 mg. The drug will be produced at the group’s formulations manufacturing facility at Baddi in Himachal Pradesh.

The estimated sales for Voriconazole Tablets which is used in the treatment of fungal infections, is $92.8 million, as per IMS (MATMarch 2016).

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×